Latest News - Pfizer

Friday, July 20, 2018

Game On: Head-to-head Trials to Enhance Competition in PsO Market

An increase in head-to-head trials will enhance the competition within the psoriasis market, according to GlobalData. The first major biologics that were released were anti-tumor necrosis factor (a…

Read the full story

Monday, July 02, 2018

XELJANZ Receives EU Marketing Authorization for Adults with Active PsA

The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adul…

Read the full story

Wednesday, November 22, 2017

New Analysis Provides Reassurance on Biosimilar Safety

And they’re … safe. Biosimilars, which have been available in the European Union since 2006, show no substantial differences in the reporting of safety information than their originato…

Read the full story

Friday, August 04, 2017

FDA Advisory Arm Backs XELJANZ for PsA

The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active pso…

Read the full story

Thursday, May 04, 2017

Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis

(via BusinessWire) Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ® …

Read the full story

Wednesday, December 14, 2016

FDA Approved Eucrisa (Crisaborole) for AD

The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older.  Eucrisa, applied topically twice daily, …

Read the full story

Tuesday, October 18, 2016

Biosim Update: Pfizer to Begin Shipping INFLECTRA in Late November 2016

Pfizer Inc. will begin shipment of INFLECTRA (infliximab-dyyb) for injection, a biosimilar of REMICADE1 (infliximab) to wholesalers in the United States in late November 2016. INFLECTRA will be the…

Read the full story

Thursday, September 22, 2016

Alopecia Areata Breakthrough: Two Studies Suggest JAK inhibitors May Spur Hair Regrowth

Taken together, two new studies suggest that JAK inhibitors may play a role in treating alopecia areata. Two JAK inhibitors are already approved by the U.S. FDA, XELJANZ® (tofacitinib citr…

Read the full story

Thursday, June 02, 2016

Pfizer/Anacor Merger To Fuel Already Robust AD Pipeline

For years, there were few, if any, promising new treatments for atopic dermatitis (AD), but today the pipeline is robust, and a Pfizer-Anacor merger may help both of the companies’ pipeline cand…

Read the full story

Wednesday, April 06, 2016

Pfizer-AGN Deal Off

UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses ass…

Read the full story

Friday, March 18, 2016

Bernie Sanders Urges Treasury to Block Pfizer-AGN Merger

Democratic presidential hopeful Bernie Sanders is urging the US Treasury to prevent the Pfizer-Allergan deal, according to media reports. Calling it a ‘tax scam” in a letter to the…

Read the full story